CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Novo Nordisk A/S (NYSE: NVO) Investors to Inquire About a Securities Fraud Class Action by September 30, 2025

Core Insights - Berger Montague PC is investigating claims against Novo Nordisk A/S under federal securities laws following a class action lawsuit filed against the company [1][2]. Company Performance - On July 29, 2025, Novo Nordisk lowered its sales and profit guidance for the second half of fiscal 2025, attributing this to persistent use of compounded GLP-1s, slower-than-expected market expansion, and increased competition for its products Wegovy® and Ozempic® [3]. - Following the announcement, Novo's stock price fell from $69.00 to $53.94 per share, marking a one-day decline of over 21% [3]. Investor Information - Investors who purchased or acquired Novo securities between May 7, 2025, and July 28, 2025, have until September 30, 2025, to seek appointment as lead plaintiff representative of the class [2].